Equities analysts predict that Alkermes Plc (NASDAQ:ALKS) will report ($0.04) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Six analysts have issued estimates for Alkermes’ earnings, with the lowest EPS estimate coming in at ($0.14) and the highest estimate coming in at $0.00. Alkermes posted earnings of $0.31 per share during the same quarter last year, which suggests a negative year over year growth rate of 112.9%. The firm is scheduled to report its next earnings report on Wednesday, February 13th.
On average, analysts expect that Alkermes will report full year earnings of $0.23 per share for the current financial year, with EPS estimates ranging from $0.13 to $0.28. For the next financial year, analysts forecast that the company will post earnings of $0.58 per share, with EPS estimates ranging from ($0.06) to $0.98. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that cover Alkermes.
Alkermes (NASDAQ:ALKS) last posted its quarterly earnings results on Tuesday, October 23rd. The company reported $0.07 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.08) by $0.15. The business had revenue of $248.72 million for the quarter, compared to analyst estimates of $236.70 million. Alkermes had a negative return on equity of 0.12% and a negative net margin of 13.23%. The business’s revenue was up 14.4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.03 EPS.
Several brokerages have weighed in on ALKS. Zacks Investment Research raised Alkermes from a “hold” rating to a “buy” rating and set a $48.00 target price on the stock in a research report on Wednesday, October 10th. BidaskClub raised Alkermes from a “hold” rating to a “buy” rating in a research report on Friday, September 28th. ValuEngine raised Alkermes from a “sell” rating to a “hold” rating in a research report on Friday, October 26th. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $46.00 target price on shares of Alkermes in a research report on Tuesday, October 23rd. Finally, Cowen reaffirmed a “buy” rating and issued a $58.00 target price on shares of Alkermes in a research report on Tuesday, October 30th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company. Alkermes has a consensus rating of “Hold” and an average price target of $50.54.
In other news, Director Paul J. Mitchell sold 1,000 shares of the stock in a transaction on Monday, December 3rd. The stock was sold at an average price of $36.45, for a total value of $36,450.00. Following the completion of the transaction, the director now owns 8,000 shares of the company’s stock, valued at $291,600. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In the last three months, insiders sold 3,000 shares of company stock valued at $116,380. Company insiders own 5.34% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC grew its stake in shares of Alkermes by 123.7% in the third quarter. Tower Research Capital LLC TRC now owns 2,908 shares of the company’s stock worth $123,000 after purchasing an additional 1,608 shares in the last quarter. Nordea Investment Management AB bought a new position in shares of Alkermes in the third quarter worth $183,000. LPL Financial LLC bought a new position in shares of Alkermes in the third quarter worth $212,000. Crossmark Global Holdings Inc. bought a new position in shares of Alkermes in the third quarter worth $220,000. Finally, Hsbc Holdings PLC bought a new position in shares of Alkermes in the third quarter worth $235,000.
ALKS stock opened at $34.01 on Friday. The company has a current ratio of 2.85, a quick ratio of 2.56 and a debt-to-equity ratio of 0.24. The company has a market cap of $5.40 billion, a P/E ratio of -91.92 and a beta of 1.53. Alkermes has a 12-month low of $32.61 and a 12-month high of $71.22.
Alkermes Company Profile
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) and BYDUREON BCise for the treatment of type 2 diabetes.
Further Reading: How to use beta for portfolio diversification
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.